---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-139476"
form_type: "8-K"
ticker: "ALGS"
cik: "0001799448"
company_name: "Aligos Therapeutics, Inc."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T23:25:01.279650+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aligos Therapeutics Chief Medical Officer Matthew McClure resigns effective May 9, 2024

## Summary
- Matthew McClure resigned as Chief Medical Officer on May 9, 2024.
- No replacement or interim CMO was announced in the filing.
- The departure follows Aligos's focus on antiviral therapeutics; impact on pipeline unclear.

## SEC filing metadata
- accession: 0001193125-24-139476
- form_type: 8-K
- ticker: ALGS
- cik: 0001799448
- company_name: Aligos Therapeutics, Inc.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799448/000119312524139476/0001193125-24-139476-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799448/000119312524139476/d793808d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-139476
- JSON: https://secwatch.observer/filing/0001193125-24-139476.json
- Plain text: https://secwatch.observer/filing/0001193125-24-139476.txt

## Key facts
- Executive change
  Matthew McClure resigned as Chief Medical Officer at Aligos Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Medical Officer
  source text: On May 9, 2024, Matthew McClure notified Aligos Therapeutics, Inc. (the “Company”) of his resignation from his position as Chief Medical Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1799448/000119312524139476/0001193125-24-139476-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.